Overview

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Status:
Completed
Trial end date:
2019-05-29
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female subjects
Phase:
Phase 1
Details
Lead Sponsor:
Idorsia Pharmaceuticals Ltd.
Treatments:
Clopidogrel
Prasugrel Hydrochloride
Ticagrelor
Ticlopidine